Catch Team Forge at BioProcess International! Hear exciting science from our experts September 23-26 in Boston. ?? Don Belcher, Ph.D., will be presenting a poster on “Advanced Fermentation and Purification Strategies for Scalable Plasmid DNA Production” ?? Aghiad Alkhiamy will be presenting a poster on “Enhanced Purification for Scalable rAAV production: Forge’s Streamlined Process for Efficient rAAV Purification” ?? Jeff Habel, Ph.D., will be presenting a poster on “Transfection Optimization with Plasmid DNA Ratio for Manufacturing FBX-101 (rAAV expressing GALC)” Learn more about the conference here ?? https://hubs.li/Q02PL5hq0
关于我们
Forge, a member of Ajinomoto Bio-Pharma Services, is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. We bring expertise in gene therapy manufacturing and therapeutics development to the table, helping champion teams that are navigating the long road from the lab bench to the bedside. With a patients-first approach, we are forging new models for working together to better accelerate these transformative medicines to reach those who need them most.
- 网站
-
https://www.forgebiologics.com
Forge Biologics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Columbus,Ohio
- 类型
- 私人持股
- 创立
- 2020
- 领域
- AAV、Gene Therapy、Biotech和cGMP
地点
-
主要
US,Ohio,Columbus
Forge Biologics员工
动态
-
We are thrilled to announce that Ryan Heil, Director of Quality Management, has been named a winner of the 2024 Veeva Systems Hero Awards. This award celebrates trailblazers across different industries who bring creativity and innovation to drive meaningful improvements in their work. Ryan's exceptional dedication to excellence and technical expertise have already made a lasting impact on the quality department at Forge and the work we do for our clients. Beyond his professional achievements, Ryan is a compassionate, generous, and thoughtful leader, truly deserving of the Veeva Hero Award. Join us in congratulating Ryan on this well-deserved recognition!
-
We are excited to announce a new stage of growth at Forge! After nearly five years of visionary leadership, our President and CEO, Timothy J. Miller, Ph.D. (he/him), is stepping down from the company he co-founded in 2020. John Maslowski, long-time gene and cell therapy industry veteran and current Chief Commercial Officer, has been appointed as President and CEO effective October 1. As we continue to expand our services and enhance operational efficiencies, John’s extensive experience as a biopharmaceuticals executive will guide us through this exciting new phase of growth. Since co-founding Forge, Dr. Miller has built an incredible foundation driven by innovation and a patient-first mission. We are deeply grateful for his leadership and lasting impact. Read the full press release to learn more about John and this transition: https://hubs.li/Q02Ph-DW0
-
We are proud to unite with the Muscular Dystrophy Association as its AAV development and manufacturing partner to help accelerate treatments for people living with muscular dystrophy, ALS, and related neuromuscular diseases through its Kickstart Program. Read the full press release here ?? https://hubs.li/Q02P4_dB0
-
Coming next week! Forge’s Chief Financial Officer, Christina Perry, will be speaking at the 54th annual Midwest U.S. – Japan Association Conference. Ms. Perry will join leading Midwest healthcare experts on the Life Science panel, Global Innovations for a Healthier Future. Learn more about the conference here ?? https://bit.ly/47iGgPh
-
?? Curious about what happens inside "the Hearth," our state-of-the-art facility? Check out the exclusive tour and see how Forge is transforming gene therapy manufacturing inside our 200,000 sq. ft. space. Want to learn more? Explore our full range of services on our website here ?? https://bit.ly/3Xywwgw
-
Don’t miss this! Our CEO Timothy J. Miller, Ph.D. (he/him), will be speaking at the American Society of Gene and Cell therapy’s policy summit. Dr Miller will be part of the Hot Topics in Clincial Development: Risk-Benefit Analysis for CGTs panel. Here are the details ?? ?? Tuesday, September 24th ? 9:50 am ?? Washington D.C. and virtual Learn more about the summit here ?? https://bit.ly/4cSIUwn
-
September marks Leukodystrophy Awareness Month. Throughout the month, we’ll be shining a light on individuals and families affected by Krabbe disease, a rare leukodystrophy, as well highlighting key facts and advancements being made in our effort to drive meaningful solutions for patients. Learn more about our patient advocacy work here ?? https://bit.ly/3Ze2foD #KrabbeAwareness #LeukodystrophyMonth
-
?? ICYMI: 23 Questions with Forge - GMP manufacturing edition! Gown up and join two of our GMP manufacturing experts, Aga Gascoyne, PhD, and Ashley Craddick, as they take you into our clean rooms. Discover how our specialized teams collaborate to ensure the safe production and delivery of our clients' gene therapies during this critical manufacturing phase. Read the full blog here ?? https://hubs.ly/Q02N67D30
-
What’s better than PDA Midwest, ATMP’s, and Pizza in Ohio? ? We’re honored to host the next PDA Midwest meeting, featuring networking opportunities, a discussion on Contamination Control Strategies for ATMP manufacturing, and a tour of our state-of-the-art facility. ? ? ?? Wednesday, September 18 ? 6:00-8:30 PM ?? Forge Biologics ? Register here! https://lnkd.in/d2z8TxCT